OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, today announced that it has completed the submission on clinical and biomarker data from the Company's Phase 2b clinical trial of OST-HER2 in the prevention of delay of recurrent, fully resected, pulmonary metastatic osteosarcoma to the U.S. Food & Drug Administration in preparation for the Company's upcoming Pre-BLA Meeting, reported full-year 2025 financial results for the period ended December 31, 2025 and provided a business update. The Company expects the Pre-BLA Meeting to occur in May 2026.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.